Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
On Tuesday, March 10, 2026, PolyPid (NASDAQ:PYPD) presented at The Citizens Life Sciences Conference 2026, highlighting its strategic initiatives and future plans. The conference call underscored the ...
PolyPid Ltd. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.34. Operator: Greetings and welcome to PolyPid’s Fourth Quarter and Full Year 2025 Conference Call.
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
ATLANTA, GA, UNITED STATES, January 13, 2026 / EINPresswire.com / — Enlighten Clinical Solutions today announced the official release of its integrated electronic Trial Master File (eTMF) module, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results